6,076 Shares of Johnson & Johnson $JNJ Bought by Vista Capital Partners Inc.

Vista Capital Partners Inc. bought a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 6,076 shares of the company’s stock, valued at approximately $1,609,000.

A number of other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP boosted its position in Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after buying an additional 2,513,321 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Johnson & Johnson by 11.5% during the third quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock worth $3,927,981,000 after buying an additional 1,530,070 shares in the last quarter. Amundi increased its holdings in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Finally, Jupiter Topco LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $1,967,399,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.0%

JNJ opened at $285.78 on Monday. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $687.95 billion, a PE ratio of 43.30, a PEG ratio of 2.82 and a beta of 0.22. Johnson & Johnson has a 1-year low of $193.55 and a 1-year high of $288.11. The firm has a 50-day moving average price of $266.97 and a two-hundred day moving average price of $249.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the previous year, the firm posted $2.80 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a report on Thursday, October 15th. Wells Fargo & Company raised their price target on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research report on Monday, August 3rd. Erste Group Bank downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Finally, Guggenheim reissued a “buy” rating and issued a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

View Our Latest Research Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.